Alex Harding, M.D., M.B.A.

Alex Harding, M.D., M.B.A. serves as Senior Vice President and Head of Business Development. He brings extensive leadership experience in biopharma business development and corporate strategy to CRISPR Therapeutics. Most recently, he served as Senior Vice President of Business Development and Corporate Strategy at Remix Therapeutics, a biotechnology company developing small molecule therapies to modulate RNA processing. At Remix, Alex co-founded the company, sourced technology, helped set the strategic direction, and led financing efforts, raising over $150M from a top-tier investor syndicate (Seed, Series A, Series B). He also led business development processes, resulting in a collaboration with Janssen Pharmaceuticals. Before Remix, he was a Senior Associate at Atlas Venture, where he helped to start new biotech companies, including Triplet Therapeutics, Vedere Bio, Third Harmonic Bio, and Remix Therapeutics. Alex received an M.D. from Johns Hopkins School of Medicine, with honors, and completed his residency in internal medicine at Massachusetts General Hospital. Additionally, He received an M.B.A. from Harvard Business School and a B.A. from Yale University. He also continues to practice medicine at a community health center in Chelsea, Massachusetts.

Previous Next